Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.

ABSTRACT:

Background

Irinotecan-based chemotherapy is a standard backbone of therapy in patients with metastatic colorectal cancer (CRC) or gastric cancer (GC). However, there is still a paucity of information concerning the efficacy and safety of irinotecan-based regimens in elderly patients.

Patients and methods

Using the patient cohort (n = 1,545) from the UGT1A1 genotype study, we compared the efficacy and safety between elderly and nonelderly patients with metastatic CRC (n = 934) or GC (n = 611) who received first- or second-line FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) chemotherapy.

Results

Despite lower relative dose intensity in elderly patients, progression-free survival and overall survival were similar between elderly (age ≥70

SUBMITTER: Kim JW 

PROVIDER: S-EPMC5344645 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature